Raise awareness about food allergies, anaphylaxis, and management of allergic reactions.

Awareness campaigns should be launched at both pan-European and national levels to improve understand on the risks of allergic reactions, the proper response in the cases of anaphylaxis, and the potentially life-saving effect of timely treatment.

Allow for emergency medicines, such as AAIs, to be made available in public places where risk of allergic reaction could be higher.

Organisations such as schools, offices, restaurants, and sports venues should be permitted to keep emergency medicines such as AAIs on hand without the need for a prescription designated to a particular person. This change is in line with the EU 4 Health program’s stated goals, which include enhancing the availability and accessibility of medicinal products and medical devices. The decision to acquire AAIs for emergency use can remain voluntary and be left up to the organisation.

While Ireland and Portugal have recently adopted policies in line with those in the US, UK, and Australia, laws in most Member States still forbid acquisition of AAIs for public places.

Create and promote EU-wide, evidence-based guidelines for allergy management and response to anaphylaxis, including recommendations around the emergency administration of AAIs.

European-level guidance covering diagnosis, treatment, management, and prevention of allergies is essential. This guidance should include a harmonized framework for the acquisition, storage, and procedures for administration of AAIs in public places.

Currently, only a few Member States have such guidelines, and they are varied and fragmented between countries.